Skip to content
Open access

Low-dose deferasirox for lower-risk myelodysplastic syndromes after erythropoiesis-stimulating agents (ESA) failure: results of the phase II LODEFI study.

Sep 2026 · Haematologica · 0 citations · 3 references
Medicine

Abstract

Not available.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.